John Devane, PhD

Dr. John Devane currently serves as a scientific advisor and board member to Sebela Pharmaceuticals. He is also a board member of Saol Therapeutics and is an advisor to Avego Healthcare Capital. Previously, Dr. Devane was Chief Scientific Officer with Horizon Pharma Ireland Ltd., and from 2012 to 2014, he served as CSO to Vidara Therapeutics Research Ltd. Dr. Devane was part of the founding team of AGI Therapeutics plc. and served as its Chief Executive Officer from 2004 to 2012. Additionally, Dr. Devane founded and led Athpharma Ltd. as Chief Executive Officer from 2002 to 2005. Dr. Devane worked for Elan Corporation from 1981 to 2001 and held various senior leadership positions, including Executive Vice President of Research and Development from 1993 to 2001 and Senior Vice President of Clinical and Regulatory, where he led key clinical trial programs in the U.S. and negotiated NDA approvals directly with the FDA. From 1990 to 2001, Dr. Devane and his team were responsible for 6 NDA and 3 ANDA approvals. Dr. Devane has had a long career designing and successfully delivering major product development programs spanning the full range of drug development. He has a deep knowledge in pharmacology, drug delivery, clinical development, regulatory affairs and intellectual property. Dr. Devane is the inventor/co-inventor on many granted and pending patent applications and has also been widely published in the scientific/medical literature.

Dr. Devane’s graduate and post-graduate scientific training was conducted at University College in Dublin, Ireland. He holds a diploma in Accounting & Finance (ACCA) and is a certificate/diploma holder from the Institute of Directors (UK).